Louisville Hematology Highlights


 

Current Standard of Care and Future Directions in CLL

111 views
February 26, 2024

Chapters

Changes in CLL Treatment & NCCN Guidelines

00:00

BTK Inhibitors Evolution & FDA-Approved Drugs

01:50

ELEVATE TN: Acalabrutinib's Frontline Approval

04:25

SEQUOIA Trial & Zanubrutinib's Frontline Efficacy

08:34

Data from CLL13 and CLL14 Trials

11:27

ELEVATE-RR Trial Compares Acalabrutinib & Ibrutinib

18:47

ALPINE Study & Zanubrutinib vs. Ibrutinib Safety

20:25

Emerging Therapies: Pirtobrutinib & Non-Covalent BTK Inhibitors

23:44

Comments 0
Login to view comments. Click here to Login